The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO GI 2026 | Phase II study of durvalumab + olaparib in patients with metastatic pancreatic cancer and DDR genes
Teresa Macarulla, MD, Vall d’Hebron University Hospital, Barcelona, Spain, discusses findings from a Phase II trial of durvalumab plus olaparib in patients with metastatic pancreatic cancer and DNA damage repair (DDR) genes alterations. Durvalumab plus olaparib demonstrated promising and durable antitumor activity, with a manageable safety profile. Further research is needed to better identify patients with prolonged disease control. This interview took place at the 2026 American Society of Clinical Oncology Gastrointestinal Cancers Symposium in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
